Note: This story was updated May 16, 2023, to correct the duration of ANX005 infusions. Only the first loading dose…
Articles by Lindsey Shapiro, PhD
The last patient has completed the final visit in the Phase 3 PROOF-HD trial testing oral pridopidine for…
Enrollment is underway in a Phase 2 clinical trial testing Roche’s therapeutic candidate tominersen in people with…
Long-term treatment with Austedo (deutetrabenazine) safely led to sustained reductions in chorea for people with Huntington’s disease, including those…
A data safety monitoring committee has recommended that enrollment of the highest dosing group resume in the European Phase 1/2…
A single injection of Wave Life Science‘s experimental therapy WVE-003 was found, at either of the two lowest tested…
Social support for children of a parent with Huntington’s disease from someone other than a caregiver is important in…
A Phase 2 trial of pepinemab failed to significantly improve certain cognitive abilities in people with prodromal to early…
AMT-130, uniQure’s investigational gene therapy for Huntington’s disease, was generally well-tolerated and led to reductions in the levels…
The first two dosing groups in a Phase 1/2 trial of AMT-130, uniQure’s investigational gene therapy for Huntington’s…